Equities research analysts expect Inogen Inc (NASDAQ:INGN) to post sales of $62.01 million for the current quarter, according to Zacks. Three analysts have issued estimates for Inogen’s earnings, with estimates ranging from $61.71 million to $62.20 million. Inogen reported sales of $50.85 million in the same quarter last year, which indicates a positive year over year growth rate of 21.9%. The business is expected to announce its next earnings results after the market closes on Tuesday, February 27th.

On average, analysts expect that Inogen will report full year sales of $62.01 million for the current year, with estimates ranging from $242.00 million to $247.80 million. For the next year, analysts forecast that the business will post sales of $297.74 million per share, with estimates ranging from $286.10 million to $304.27 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side analysts that that provide coverage for Inogen.

Inogen (NASDAQ:INGN) last announced its earnings results on Tuesday, November 7th. The medical technology company reported $0.33 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.29 by $0.04. Inogen had a net margin of 11.36% and a return on equity of 13.37%. The business had revenue of $69.00 million for the quarter, compared to analyst estimates of $63.55 million. During the same quarter in the previous year, the firm posted $0.25 earnings per share. Inogen’s revenue was up 26.8% compared to the same quarter last year.

A number of brokerages recently issued reports on INGN. BidaskClub raised shares of Inogen from a “sell” rating to a “hold” rating in a research report on Wednesday, January 24th. Zacks Investment Research raised shares of Inogen from a “hold” rating to a “buy” rating and set a $131.00 target price on the stock in a research report on Thursday, November 9th. Leerink Swann reaffirmed an “outperform” rating and set a $120.00 target price (up previously from $115.00) on shares of Inogen in a research report on Wednesday, November 8th. Finally, Needham & Company LLC boosted their price target on shares of Inogen from $108.00 to $125.00 and gave the company a “strong-buy” rating in a report on Wednesday, November 8th. Five investment analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $103.29.

Inogen (INGN) opened at $119.37 on Thursday. Inogen has a 52-week low of $64.84 and a 52-week high of $130.05. The stock has a market cap of $2,456.02, a price-to-earnings ratio of 97.05, a P/E/G ratio of 3.99 and a beta of 1.02.

In other news, EVP Matt Scribner sold 2,500 shares of the company’s stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $112.35, for a total value of $280,875.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Byron Myers sold 35,000 shares of the company’s stock in a transaction dated Friday, November 17th. The stock was sold at an average price of $116.77, for a total transaction of $4,086,950.00. Following the completion of the sale, the executive vice president now directly owns 48,600 shares in the company, valued at approximately $5,675,022. The disclosure for this sale can be found here. Insiders sold a total of 113,651 shares of company stock worth $13,299,463 in the last three months. Insiders own 5.31% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Lenox Wealth Advisors Inc. acquired a new position in Inogen during the 4th quarter worth about $100,000. Steward Partners Investment Advisory LLC lifted its position in Inogen by 1,000.0% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 1,100 shares of the medical technology company’s stock worth $130,000 after buying an additional 1,000 shares in the last quarter. Ameritas Investment Partners Inc. lifted its position in Inogen by 6.1% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 1,495 shares of the medical technology company’s stock worth $143,000 after buying an additional 86 shares in the last quarter. Simplex Trading LLC acquired a new position in Inogen during the 4th quarter worth about $153,000. Finally, LS Investment Advisors LLC lifted its position in Inogen by 138.6% during the 4th quarter. LS Investment Advisors LLC now owns 1,515 shares of the medical technology company’s stock worth $180,000 after buying an additional 880 shares in the last quarter.

ILLEGAL ACTIVITY NOTICE: This report was first published by Daily Political and is owned by of Daily Political. If you are accessing this report on another website, it was illegally copied and reposted in violation of international trademark & copyright legislation. The original version of this report can be read at https://www.dailypolitical.com/2018/02/07/62-01-million-in-sales-expected-for-inogen-inc-ingn-this-quarter.html.

About Inogen

Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.

Get a free copy of the Zacks research report on Inogen (INGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.